The CIZ1B Biomarker

Transforming Lung Cancer Detection

PATIENTS
HEALTHCARE PROFESSIONALS

Advancing Early Detection with the Power of CIZ1B

At Cizzle Bio, we’re on a mission to revolutionize early lung cancer detection with our groundbreaking CIZ1B biomarker test. This minimally invasive, highly accurate blood test is designed to detect lung cancer at its earliest stages—before symptoms appear and when treatment is most effective. The power of early detection gives patients a crucial advantage in their fight against the disease.

PROBLEM

Why Early Detection Matters

Every day, nearly 5,000 lives are lost to lung cancer, with most cases diagnosed at late stages when treatment options are limited. Yet, early detection can make all the difference in giving patients better outcomes.

CHALLENGES

  • HIGH MORTALITY

    Lung cancer is the leading cause of cancer deaths worldwide, often due to late diagnosis.

  • LOW SCREENING RATES

    Only 5.8% of the 14.2 million Americans recommended for annual screening receive a low-dose CT (LDCT) scan, the current standard protocol for early detection.

  • POTENTIAL FOR CHANGE

    Early diagnosis significantly improves survival rates, offering patients the best chance of survival.

SOLUTION

A Breakthrough in Early Lung Cancer Detection

The Science Behind CIZ1B

The discovery of the CIZ1B biomarker began with the pioneering research of Professor Dawn Coverley, Ph.D., at the University of York. After more than two decades studying cancer biology, her team identified a variant of the CIZ1 protein involved in DNA replication—CIZ1B—strongly linked to early-stage lung cancer. This insight laid the foundation for a novel approach to lung cancer detection focused on early intervention and improved survival.

2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2005Founded by Professor Dawn Coverley.
2006 Early funding secured.
2021Listed on London Stock Exchange.
2025CIZ1B test nearing launch.

Swipe left to view more

A Journey of Innovation

In 2005, Professor Coverly founded Cizzle Biotech Limited to turn this breakthrough into a diagnostic tool for early detection. Backed by Yorkshire Cancer Research, the White Rose Seed Fund, and other early supporters, Cizzle Biotech developed its first CIZ1B blood test prototype. The company’s progress culminated in its 2021 listing on the London Stock Exchange, marking its emergence as a leader in early cancer detection.

Cizzle Bio, Inc. was established in 2024 to bring this transformative test to patients in the United States. The U.S. team secured the exclusive licensing rights from Cizzle Biotech in June 2024, initiating the process to commercialize and validate the test in U.S. clinical environments.

How CIZ1B Transforms Lung Cancer Screening

Minimally Invasive, Cost-Effective, and Highly Accurate

Our CIZ1B biomarker test offers a powerful alternative to traditional early detection methods such as low-dose CT (LDCT) scans. Unlike LDCT, which can lead to false positives and costly follow-ups, our biomarker-based blood test is accurate, accessible, and minimally invasive. With 95% sensitivity for Stage I detection1 and Negative Predictive Value (NPV) at 96%1, the CIZ1B test provides quick, reliable results that support more informed clinical decision-making.

0%

Sensitivity 1

0%

NPV 1

Benefits of CIZ1B

  • REDUCED RADIATION

    Minimizes the need for repeated CT scans and unnecessary radiation exposure.

  • ACCURATE & ACTIONABLE

    Supports earlier, faster clinical decisions.

  • MINIMALLY INVASIVE

    Requires only a simple blood draw requiring less than a tablespoon of blood.

  • CONVENIENCE

    No need for specialized facilities, making early detection more accessible.

FOR HEALTHCARE PROVIDERS & PATIENTS

  • COST-EFFECTIVE

    For healthcare providers, this means a cost-effective solution that frees up resources and enhances clinical assessment.

  • ACCESSIBLE

    For patients, the CIZ1B biomarker test offers an accessible, proactive approach to early detection of lung cancer that increases peace of mind.

Collaborations Fueling Cizzle Bio’s Mission

Backed by collaborations with leaders like Moffitt Cancer Center and BBI Solutions, Cizzle Bio is equipped to bring the CIZ1B biomarker test to the forefront of lung cancer diagnostics. These collaborations extend our reach and ensure that more patients and healthcare providers have access to life-saving technology.

A Mission to Make Early Detection the Standard

Our commitment to innovation goes beyond a single test. Cizzle Bio continues to explore new early detection biomarkers for other cancers, ensuring that more individuals have access to leading-edge diagnostic tools.  We’re working toward a future where early detection is routine, accessible, and affordable for all.

Saving Lives, One Test at a Time

At Cizzle Bio, our driving purpose—Detect Early. Save Lives. —inspires every breakthrough we deliver. By giving patients the power of early action and equipping physicians with precision diagnostics, we’re changing the course of cancer care and saving more lives.

FOR PATIENTS

Take proactive steps—learn how to get tested.

Learn More 
FOR PHYSICIANS

Learn more about how to access our CIZ1B biomarker tests.

Learn More

Stay Updated on the Latest Research

Visit our Resources Page to explore in-depth articles, cutting-edge research, and the latest updates on our journey to make early cancer detection the standard of care.

Stay updated on our advancements in technology, community impact, and industry leadership.

  • Coverley D, Higgins G, West D, et al. A quantitative immunoassay for the lung-cancer biomarker CIZ1b in patient plasma. Clin Biochem. 2017;50(6):336-343.

References: